CD19 Antibody (PSH03-94)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-32130
Recombinant Monoclonal Antibody
Key Product Details
Species Reactivity
Validated:
Mouse
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation, Western Blot
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Rabbit IgG Clone # PSH03-94
Concentration
1 mg/ml
Product Summary for CD19 Antibody (PSH03-94)
Immunogen
Recombinant protein within mouse CD19 protein. (Uniprot: P25918)
Localization
Cell membrane, Membrane raft.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG
Theoretical MW
60 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for CD19 Antibody (PSH03-94)
Immunoprecipitation: CD19 Antibody (PSH03-94) [NBP3-32130]
Immunoprecipitation: CD19 Antibody (PSH03-94) [NBP3-32130] - CD19 was immunoprecipitated in 0.2mg Mouse spleen tissue lysate with NBP3-32130 at 2 ug/25 ul agarose. Western blot was performed from the immunoprecipitate using NBP3-32130 at 1/1,000 dilution. Anti-Rabbit IgG for IP Nano-secondary antibody at 1/5,000 dilution was used for 1 hour at room temperature.Lane 1: Mouse spleen tissue lysate (input)
Lane 2: NBP3-32130 IP in Mouse spleen tissue lysate
Lane 3: Rabbit IgG instead of NBP3-32130 in Mouse spleen tissue lysate
Blocking/Dilution buffer: 5% NFDM/TBST
Exposure time: 17 seconds
Western Blot: CD19 Antibody (PSH03-94) [NBP3-32130]
Western Blot: CD19 Antibody (PSH03-94) [NBP3-32130] - Western blot analysis of CD19 on mouse spleen tissue lysates with Rabbit anti-CD19 antibody (NBP3-32130) at 1/1,000 dilution.Lysates/proteins at 20 ug/Lane.
Predicted band size: 60 kDa
Observed band size: 60-120 kDa
Exposure time: 30 seconds;
4-20% SDS-PAGE gel.
Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (NBP3-32130) at 1/1,000 dilution was used in 5% NFDM/TBST at 4C overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1/50,000 dilution was used for 1 hour at room temperature.
Immunohistochemistry: CD19 Antibody (PSH03-94) [NBP3-32130]
Immunohistochemistry: CD19 Antibody (PSH03-94) [NBP3-32130] - Immunofluorescence analysis of paraffin-embedded mouse spleen tissue labeling CD19 with Rabbit anti-CD19 antibody (NBP3-32130) at 1/200 dilution.The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 20 minutes. The tissues were blocked in 10% negative goat serum for 1 hour at room temperature, washed with PBS, and then probed with the primary antibody (NBP3-32130, green) at 1/200 dilution overnight at 4 ℃, washed with PBS. Goat Anti-Rabbit IgG H&L (iFluor™ 488) was used as the secondary antibody at 1/1,000 dilution. Nuclei were counterstained with DAPI (blue).
Applications for CD19 Antibody (PSH03-94)
Application
Recommended Usage
Immunohistochemistry-Paraffin
1:500
Immunoprecipitation
1-2ug/sample
Western Blot
1:1000
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS (pH7.4), 0.1% BSA and 40% Glycerol
Preservative
0.05% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: CD19
Considering the role of CD19 in BCR signaling and its expression in development from pre-B cells through plasma cells, it is understandable that CD19 dysfunction and abnormal expression is associated with numerous B cell malignancies and autoimmune disorders (1-5). CD19 expression is typically observed at relatively normal levels in B cell acute lymphoblastic leukemia (B-ALL) and chronic lymphoblastic leukemia (CLL) but is often reduced other types of lymphoma including diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) (1,2). On the other hand, CD19 expression is typically increased in autoimmune disorders such as systemic sclerosis (SSc) and multiple sclerosis (MS) as modeled by experimental autoimmune encephalomyelitis (EAE) (2). CD19 has become a therapeutic molecular target for the treatment of B cell lymphomas and autoimmune disorders using monoclonal antibodies (mAbs), bi-specific T cell engaging (BiTE) antibodies, and CD19-specific chimeric antigen receptor (CAR) T cells (1,2,4-6). Although anti-CD19 CAR T cell therapy has become the standard for the treatment of B cell malignancies, patients may experience relapse due to resistance mechanisms (6). Strategies to improve efficacy and limit relapse include combination of CAR T cell therapy with immune checkpoint inhibitors like anti-PD-1 (4,6).
References
1. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36. https://doi.org/10.1186/2162-3619-1-36
2. Li X, Ding Y, Zi M, et al. CD19, from bench to bedside. Immunol Lett. 2017;183:86-95. https://doi.org/10.1016/j.imlet.2017.01.010
3. Wentink MWJ, van Zelm MC, van Dongen JJM, Warnatz K, van der Burg M. Deficiencies in the CD19 complex. Clin Immunol. 2018;195:82-87. https://doi.org/10.1016/j.clim.2018.07.017
4. Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020;130(4):1586-1594. https://doi.org/10.1172/JCI129208
5. Penack O, Koenecke C. Complications after CD19+ CAR T-Cell Therapy. Cancers (Basel). 2020;12(11):3445. https://doi.org/10.3390/cancers12113445
6. Bouziana S, Bouzianas D. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Crit Rev Oncol Hematol. 2021;157:103096. https://doi.org/10.1016/j.critrevonc.2020.103096
Alternate Names
CD19, CVID3, Leu-12
Gene Symbol
CD19
Additional CD19 Products
Product Documents for CD19 Antibody (PSH03-94)
Product Specific Notices for CD19 Antibody (PSH03-94)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...